Literature DB >> 7813898

Familial risks for Alzheimer disease from a population-based series.

C Hirst1, I M Yee, A D Sadovnick.   

Abstract

Kaplan-Meier risks estimates are calculated and compared for two consecutive series (N1 = 840, N2 = 819) of first-degree relatives of Alzheimer disease (AD) patients diagnosed as either "probable" or "autopsy-confirmed" AD. The consistency of results increases confidence in estimates and suggests consistent case ascertainment over 8 years. Lifetime risk estimates to age 88 for the combined sample (23.4% +/- 3.0%) do not approach the 50% risk compatible with an autosomal dominant model of transmission. These results support our previous finding and suggest that an autosomal dominant gene(s) is not responsible for all cases of AD.

Entities:  

Mesh:

Year:  1994        PMID: 7813898     DOI: 10.1002/gepi.1370110406

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  4 in total

1.  Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4.

Authors:  V S Rao; A Cupples; C M van Duijn; A Kurz; R C Green; H Chui; R Duara; S A Auerbach; L Volicer; J Wells; C van Broeckhoven; J H Growdon; J L Haines; L A Farrer
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

2.  Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease.

Authors:  R E Davis; S Miller; C Herrnstadt; S S Ghosh; E Fahy; L A Shinobu; D Galasko; L J Thal; M F Beal; N Howell; W D Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

Review 3.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

4.  Beyond proof of principle: new genes for Alzheimer's disease through collaboration.

Authors:  Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Lancet Neurol       Date:  2009-11       Impact factor: 44.182

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.